Oral Cannabidiol for Opioid Withdrawal

Exclusion Criteria

• •Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for alcohol/substance use disorder other than opioid use disorder
• •Previous adverse reaction to a cannabinoid product
• •Self-report any illicit drug use or cannabinoid use in the past 7 days
• •Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse events
• •Past year suicidal behavior as assessed via the Columbia Suicide Severity Rating Scale
• •History of seizure disorder
• •Past 14 day use of any of the following contraindicated medications:
• •* Clobazam, Valproate
• •* Moderate or strong inhibitors of CYP3A4 or CYPC19 (with the exception of methadone, as outlined in the Protection Against CBD Risks section).
• •* Strong CYP3A4 or CYP2C19 inducers
• •* UGT1A9, UGT2B7, CYP1A2, CYP2C8, CYP2C9 and CYP2C19 substrates (with the exclusion of caffeine).
• •* Central nervous system (CNS) depressants that are contraindicated with Epidiolex
• •Breathalyzer that tests positive for alcohol prior to session admission
• •Self-reported consumption of grapefruit juice within 24 hours of session admission
• •Have a history of clinically significant cardiac arrhythmias or vasospastic disease
• •Have circumstances that the study investigators believe are contraindicated with study participation and/or would interfere with study participation (e.g., impending jail).
• •Moderate-severe hepatic impairment as indicated by ALT or AST levels \> 3x ULN and/or Bilirubin levels \>2x ULN as evidenced by a blood test.